Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

MLA

Tori Braun, et al. “Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.” Blood, vol. 138, Nov. 2021, p. 4554. EBSCOhost, https://doi.org/10.1182/blood-2021-148505.

APA

Tori Braun, Vanessa Dunleavy, Gayle Funk, Megumi Bailey, Neil Bailey, Krish Patel, Livia Hegerova, Tenzin Tsomo, Heidi Hohmann, Judson Hall, John M. Pagel, Sonia Glennie, Jordan Briggs, William I. Bensinger, Jennie Szeto, Daniel J. Egan, Raya Mawad, Joanna Fesler, & Joshua Mark. (2021). Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 138, 4554. https://doi.org/10.1182/blood-2021-148505

Chicago

Tori Braun, Vanessa Dunleavy, Gayle Funk, Megumi Bailey, Neil Bailey, Krish Patel, Livia Hegerova, et al. 2021. “Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.” Blood 138 (November): 4554. doi:10.1182/blood-2021-148505.